Endocyte (ECYT) Misses Q3 EPS by 20c

Endocyte (NASDAQ: ECYT) reported Q3 EPS of ($0.55), $0.20 worse than the analyst estimate of ($0.35).

• Plans to Initiate Phase 3 Registration for 177Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte –
• The University of Sydney and ANZUP Cancer Trial Group Set to Initiate Trial of 177Lu-PSMA-617 versus Cabazitaxel Under Agreement with Endocyte –
• CAR T-Cell Program on Schedule to Initiate Clinical Trial in Osteosarcoma in 2018 –

For earnings history and earnings-related data on Endocyte (ECYT) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Palo Alto Networks (PANW) Tops Q3 EPS by 6c, Offers Guidance
• Are we witnessing a fundamental or speculative rally in the S&P 500?